Regional Meetings 2020

Visiting Professors: Selection and Sequencing of Systemic Therapy in the Management of Follicular Lymphoma — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of follicular lymphoma. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services Department at or call (800) 233-6153.

Schedule of Events:

Friday, January 24, 2020
8:00 AM – 9:00 AM
Education program

Jasmine Zain, MD
University Hospitals Seidman Cancer Center
Cleveland, Ohio

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Friday, February 14, 2020
12:00 PM – 1:00 PM
Education program

Christopher R Flowers, MD, MS
Watson Clinic Cancer and Research Center
Lakeland, Florida

Buffet lunch will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised as seating is limited.

Each 1-hour session will include 2 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for follicular lymphoma (FL). Each event will employ an identical format that will include the following elements:

  • Discussion of Steering Committee Members’ Treatment Recommendations
  • Review of Available Clinical Research Findings
  • Integration of Interactive Audience Polling Results
MODULE 1 Optimizing the Care of Patients with Newly Diagnosed FL MODULE 2 Management of Relapsed/Refractory FL

Each session will conclude with a 5-minute Q&A segment


Bruce D Cheson, MD
Professor of Medicine
Deputy Chief, Division of Hematology-Oncology
Head of Hematology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Andrew M Evens, DO, MSc
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
RWJBarnabas Health
Director, Lymphoma Program
Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Nathan H Fowler, MD
Co-Director of Clinical and Translational Research
Lead, Phase I and Indolent Research Groups
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine
Harvard Medical School
Institute Physician
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Andrew D Zelenetz, MD, PhD
Medical Director, Medical Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Project Chair

Neil Love, MD
Research To Practice
Miami, Florida

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of follicular lymphoma (FL).

Learning Objectives:

  • Compare and contrast the self-reported practice patterns of lymphoma clinical investigators, and apply this knowledge to the diagnosis and treatment of FL.
  • Evaluate published research data and clinical investigator perspectives when designing an optimal induction therapeutic approach for patients with newly diagnosed FL requiring active therapy.
  • Describe the mechanism of action of and available data with the Type II CD20-targeted antibody obinutuzumab, and consider the current clinical role of this agent for newly diagnosed and relapsed/refractory FL.
  • Appreciate available Phase III data with the use of rituximab/lenalidomide as front- or later-line treatment for FL, and optimally incorporate this novel therapeutic approach into current management algorithms.
  • Individualize the use of maintenance therapeutic approaches in the management of newly diagnosed FL.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory FL.
  • Distinguish among the unique mechanisms of action, methods of administration and potential toxicities of available PI3K inhibitors to optimally integrate these agents into the care of patients with relapsed/refractory FL.
  • Develop practical strategies to prevent, recognize and ameliorate the toxicities associated with therapies routinely used in the management of FL.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech and Gilead Sciences Inc.